Clinical Trial

Efficacy and Safety of Tirzepatide for Weight Management

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes. The main questions it aims to answer are: Does tirzepatide help people lose weight? What side effects do people experience while taking tirzepatide? All participants will: Receive tirzepatide as a weekly injection, starting at 2.5 mg and gradually increasing to 15 mg. Continue the treatment for 52 weeks (12 months). Visit the clinic for regular checkups and tests. Researchers will measure changes in body weight, BMI, waist size, blood sugar, blood pressure, and cholesterol levels. They will also track any side effects and assess the participants' overall health and quality of life during the study.
Trial Details
NCT Number NCT06918405
Lead Sponsor Chittagong Medical College
Conditions Obesity and Obesity-related Medical Conditions
Enrollment 440 participants
Start Date 2025-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-09